iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin's Brazilian arm acquires 9 brand rights from Bausch Health; stock climbs ~2.5%

29 Nov 2022 , 09:25 AM

Lupin Limited (Lupin) announced that MedQuimica Industria Farmacêutica (MedQuimica), its wholly-owned subsidiary in Brazil, has signed a definitive agreement to acquire all rights to 9 medicines from BL Industria tica Ltda., Bausch Health Companies Inc.’s subsidiary.

MedQuimica will acquire the rights to nine products as part of the transaction, including Limbitrol, Melleril, and Dalmadorm for Central Nervous System conditions, Bacrocin, Glyquin, Solaquin, Oxipelle, Cuprimine for the treatment of Wilson’s disease, and Efurix as topical oncological treatments. This move demonstrates the company’s dedication to making healthcare solutions available to all patients.

“The acquired brands are well positioned and recognised among doctors and other medical fraternity members in Brazil for their dependability, safety, and trustworthiness,” said Alexandre Franca, Managing Director of MedQuimica.

MedQuimica Pharmaceutical Industries has been in business for 47 years, with its headquarters in the Juiz de Fora Industrial District. Medqumica develops an extensive line of both solid and liquid medicines in Brazil, categorising them into five categories: OTC (over-the-counter medicines), Branded Generics, Hospital, Generics, and Food Supplements.

At around 9.19 AM, Lupin was trading at Rs751 up by 2.36% from its previous closing of Rs733.70 on the BSE. The scrip opened at Rs747 and has touched intraday high and low of Rs752.55 and Rs740.25 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Lupin Acquisition
  • Lupin Brand Acquisition
  • Lupin News
  • Lupin Stock
  • Lupin Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Oil prices hold firm despite mixed signals
17 Jul 2024|10:51 AM
Dollar weakens on Fed cut expectations
17 Jul 2024|09:54 AM
Sensex and Nifty end in green
16 Jul 2024|04:34 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.